Search
# Popular search #
# Popular search #
Founded R&D Center - Beijing Gan & Lee Biotechnology Co., Ltd. (later became Gan & Lee Pharmaceuticals)
Completed the construction of the world's 3rd largest recombinant human insulin production base
Successfully developed China's 1st fast-acting human insulin analog - Prandilin? (Lispro)
Successfully developed China's 1st long-acting human insulin analog - Basalin? (Glargine)
Successfully developed China's 1st premixed human insulin analog - Prandilin ? 25 (Lispro 25R)
Company was restructured and renamed to“Gan & Lee Pharmaceuticals Co., Ltd.”
Patents were obtained for the Molecular Chaperone Technology in China and PCT patent was obtained in the US
Received production approval and GMP certificate for Basalin? from the NMPA (before CFDA)
Basalin? went on sale
Basalin? entered the international market, including Egypt, Pakistan, Mexico, etc.
The company's sales revenue exceeded RMB100 million
China's 1st independently developed insulin injection pen-Insulin Pen was launched
The company completed the shareholding transformation and its name was changed to “Gan & Lee Pharmaceuticals”
China's 1st premixed human insulin analog Prandilin? 25 was launched
Founded Gan & Lee Pharmaceuticals USA
Completed the construction of the new insulin analog manufacturing plant in Beijing
Insulin glargine was allowed by the FDA to proceed with Phase I clinical study in US
Basalin passed Europe's QP inspection and was allowed to proceed with Phase I and Phase III clinical trials in Europe
Gan & Lee attended the 78th American Diabetes Annual Conference (ADA) as the first Chinese pharmaceuticals to attend the conference
Gan & Lee concluded a commercialization and supply agreement with Sandoz, a subsidiary of Novartis on biosimilar versions of insulins used in patients with type 1 and type 2 diabetes
Recombinant insulin lispro was allowed by the FDA & European Medicines Agency to proceed with Phase I and Phase III clinical trials in the US and Europe
Gan & Lee was Initially listed on the A-share index on the Shanghai Stock Exchange
Aspart was approved for listing in China
Started the construction of Gan & Lee Linyi Production Base
Phase 1 Drug Candidate GLR2007 has been Granted Orphan Drug Designation and Fast Track Designation by the US FDA
Gan & Lee Announces New Partnership with the International Diabetes Federation
EMA granted orphan drug designation for GLR2007
Mixed Protamine Human Insulin Injection (30R) from Gan & Lee Pharmaceuticals is listed
GZR18, a GLP-1 RA, began the phase I clinical trial in China and the US.
The site you are about to visit is maintained by a third party who is responsible for its content.
This link is provided on the Gan & Lee website as a service to our visitors. Gan & Lee is not responsible for the privacy policy of any third-party websites. Gan & Lee encourages visitors to read the privacy policy of every website that you may visit.